PRESS RELEASE

Q4 2024 — Press release

Q4 2024PDF · 15 pages289 KB
- 1 -
News Release
____________________________________________________________________________
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
- Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth
Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9%
- Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-
GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business
Development Transactions
- Full-Year Worldwide Sales Were $64.2 Billion, an Increase of 7% From Full Year 2023;
Excluding the Impact of Foreign Exchange, Growth Was 10%
o KEYTRUDA Sales Grew 18% to $29.5 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 22%
o WINREVAIR Sales Were $419 Million
o Animal Health Sales Grew 4% to $5.9 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 8%
o GARDASIL/GARDASIL 9 Sales Declined 3% to $8.6 Billion; Excluding the Impact
of Foreign Exchange, Sales Declined 2%
- Full-Year 2024 GAAP EPS Was $6.74; Non-GAAP EPS Was $7.65; GAAP and Non-
GAAP EPS Include a Net Charge of $1.28 per Share Related to Certain Business
Development Transactions
- In the Fourth Quarter:
o Announced Positive Topline Results From Pivotal Phase 3 Trial of Subcutaneous
Pembrolizumab With Berahyaluronidase Alfa
o Received FDA Acceptance of Biologics License Application for Clesrovimab, an
Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants
From RSV Disease During Their First RSV Season
o Augmented Diverse Pipeline Through Exclusive Global Licenses With LaNova for
MK-2010, an Investigational Anti-PD-1/VEGF Bispecific Antibody, and With
Hansoh for MK-4082, an Investigational Oral GLP-1 Receptor Agonist
- Received Approval of GARDASIL for Males in China, in January 2025
- Full-Year 2025 Financial Outlook
o Anticipates Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion
o Expects Non-GAAP EPS To Be Between $8.88 and $9.03; Outlook Reflects a
One-Time Charge of Approximately $0.09 per Share Related to an Anticipated
Milestone Payment to LaNova
RAHWAY, N.J., Feb. 4, 2025 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the fourth quarter of 2024.

-- 1 of 15 --

- 2 -
“We delivered strong growth in 2024, reflecting demand for our innovative portfolio,
including for KEYTRUDA, which continues to benefit more patients with cancer globally, the
successful launch of WINREVAIR and strong performance of our Animal Health business,” said
Robert M. Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our
pipeline, advance key clinical programs and augment our pipeline through promising business
development. Our business remains well positioned thanks to the dedication of our talented
global team, and I am more confident than ever in our long-term growth potential.”
Financial Summary
$ in millions,
except EPS
amounts
Fourth Quarter Year Ended
2024 2023 Change
Change Ex-
Exchange
Dec. 31,
2024
Dec. 31,
2023 Change
Change Ex-
Exchange
Sales $15,624 $14,630 7% 9% $64,168 $60,115 7% 10%
GAAP net
income (loss)1 3,743 (1,226) N/M N/M 17,117 365 N/M N/M
Non-GAAP net
income that
excludes
certain
items1,2* 4,372 66 N/M N/M 19,444 3,837 N/M N/M
GAAP EPS 1.48 (0.48) N/M N/M 6.74 0.14 N/M N/M
Non-GAAP
EPS that
excludes
certain items2* 1.72 0.03 N/M N/M 7.65 1.51 N/M N/M
*Refer to table on page 9.
N/M - not meaningful
Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming
dilution was $1.48 for the fourth quarter and $6.74 for the full year of 2024. Non-GAAP EPS was
$1.72 for the fourth quarter and $7.65 for the full year of 2024. GAAP and non-GAAP EPS in the
fourth quarter of 2024 include a charge of $0.23 per share related to the execution of licensing
agreements with LaNova Medicines Ltd. (LaNova) and Hansoh Pharma (Hansoh). GAAP loss
per share and non-GAAP EPS in the fourth quarter of 2023 include a charge of $1.69 per share
related to a collaboration with Daiichi Sankyo. GAAP and non-GAAP EPS for the full years of
2024 and 2023 include charges of $1.28 and $6.21 per share, respectively, related to certain
collaborations, licensing agreements and asset acquisitions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, and income and losses from investments in equity securities. Non-
1 Net income (loss) attributable to Merck & Co., Inc.
2 Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but
not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.

-- 2 of 15 --

- 3 -
GAAP EPS in the fourth quarter and full year of 2024 also exclude a benefit due to a reduction
in reserves for unrecognized income tax benefits resulting from the expiration of the statute of
limitations for assessments related to certain federal tax return years. Non-GAAP EPS for the
full year of 2023 also excludes a charge related to settlements with certain plaintiffs in the Zetia
antitrust litigation.
Fourth-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Fourth Quarter
$ in millions 2024 2023 Change
Change Ex-
Exchange Commentary
Total Sales $15,624 $14,630 7% 9%
The negative impact of foreign exchange
was primarily due to devaluation of
Argentine peso, which was largely offset by
inflation-related price increases, consistent
with practice in that market.
Pharmaceutical 14,042 13,141 7% 8%
Increase driven by growth in oncology and
cardiovascular, partially offset by declines
in diabetes, vaccines, immunology and
virology.
KEYTRUDA 7,836 6,608 19% 21%
Growth driven by continued strong global
demand from metastatic indications,
including increased uptake in bladder and
endometrial cancers, as well as increased
global uptake in earlier-stage indications,
including triple-negative breast cancer and
non-small cell lung cancer (NSCLC). The
negative impact of foreign exchange was
primarily due to devaluation of Argentine
peso, which was largely offset by inflation-
related price increases.
GARDASIL/GARDASIL 9 1,550 1,871 -17% -18%
Decline primarily due to lower demand in
China, partially offset by higher demand in
most international regions, particularly in
Japan.
PROQUAD, M-M-R II and
VARIVAX 594 545 9% 9%
Growth primarily due to higher pricing in
the U.S. and higher tenders in certain
international markets, partially offset by
lower demand in the U.S.
JANUVIA/JANUMET 487 787 -38% -36%
Decline primarily due to lower pricing in the
U.S., as well as ongoing generic
competition in many international markets
and supply constraints in China.
BRIDION 449 429 5% 5%
Growth primarily due to higher demand in
the U.S., partially offset by generic
competition in certain international markets,
particularly in Japan and Europe.
Lynparza* 365 315 16% 18%
Growth primarily due to higher global
demand.
Lenvima* 255 226 13% 14%
Growth primarily due to timing of shipments
in certain international markets.
PREVYMIS 215 175 23% 23%
Growth primarily due to higher demand in
most markets, particularly in the U.S.
WINREVAIR 200 - - -
Represents continued uptake since
second-quarter launch in the U.S.

-- 3 of 15 --

- 4 -
Fourth Quarter
$ in millions 2024 2023 Change
Change Ex-
Exchange Commentary
VAXNEUVANCE 161 176 -9% -9%
Decline primarily driven by lower demand
in the U.S. due to competition, partially
offset by continued uptake from launches in
Europe and the Asia Pacific region.
WELIREG 160 72 122% 123%
Growth primarily driven by higher demand
in the U.S., largely attributable to ongoing
uptake of a new indication.
SIMPONI - 171 N/M N/M
Marketing rights in former Merck territories
reverted to Johnson & Johnson on Oct. 1,
2024.
Animal Health 1,397 1,278 9% 13%
Growth primarily driven by higher pricing
for both Livestock and Companion Animal
product portfolios, as well as sales related
to July 2024 acquisition of Elanco aqua
business and higher demand for Livestock
products. Approximately 3 percentage
points of the negative impact of foreign
exchange were due to devaluation of
Argentine peso, which were largely offset
by inflation-related price increases.
Livestock 889 808 10% 14%
Growth primarily driven by higher demand
for poultry products, sales related to
acquisition of Elanco aqua business, as
well as higher pricing across the portfolio.
Companion Animal 508 470 8% 10%
Growth primarily driven by higher pricing
across the product portfolio. Sales of
BRAVECTO were $209 million and $197
million in current and prior year quarters,
respectively, which represented growth of
6%, or 10% excluding impact of foreign
exchange.
Other Revenues** 185 211 -13% 3%
Decline primarily due to impact of revenue-
hedging activities and lower revenues from
third-party manufacturing arrangements,
partially offset by payments received for
out-licensing arrangements and higher
royalty income.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M – not meaningful

-- 4 of 15 --

- 5 -
Full-Year Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Year Ended
$ in millions Dec. 31, 2024 Dec. 31, 2023 Change
Change Ex-
Exchange
Total Sales $64,168 $60,115 7% 10%
Pharmaceutical 57,400 53,583 7% 10%
KEYTRUDA 29,482 25,011 18% 22%
GARDASIL/GARDASIL 9 8,583 8,886 -3% -2%
PROQUAD, M-M-R II and VARIVAX 2,485 2,368 5% 5%
JANUVIA/JANUMET 2,268 3,366 -33% -29%
BRIDION 1,764 1,842 -4% -3%
Lynparza* 1,311 1,199 9% 11%
Lenvima* 1,010 960 5% 6%
LAGEVRIO 964 1,428 -33% -28%
VAXNEUVANCE 808 665 22% 23%
PREVYMIS 785 605 30% 33%
ROTATEQ 711 769 -8% -7%
SIMPONI** 543 710 -24% -23%
WELIREG 509 218 133% 133%
WINREVAIR 419 - - -
Animal Health 5,877 5,625 4% 8%
Livestock 3,462 3,337 4% 9%
Companion Animal 2,415 2,288 6% 7%
Other Revenues*** 891 907 -2% 4%
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Marketing rights in former Merck territories reverted to Johnson & Johnson on Oct. 1, 2024.
***Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
Full-year 2024 pharmaceutical sales grew 7% to $57.4 billion. Excluding the unfavorable
impact of foreign exchange, pharmaceutical sales grew 10%. Approximately 2 percentage
points of the negative impact of foreign exchange were due to devaluation of the Argentine
peso, which were largely offset by inflation-related price increases, consistent with practice in
that market. Pharmaceutical sales growth was primarily driven by higher sales in oncology,
particularly KEYTRUDA and WELIREG, as well as increased alliance revenue from Reblozyl
and Lynparza. Higher sales in the cardiovascular franchise, reflecting the successful launch of
WINREVAIR, as well as higher sales of certain hospital acute care products, particularly
PREVYMIS, also drove revenue growth in 2024. Pharmaceutical sales growth in 2024 was
partially offset by lower sales of JANUVIA and JANUMET, primarily reflecting lower pricing in
the U.S. and generic competition in many international markets, lower sales of the COVID-19
medication LAGEVRIO, lower sales of GARDASIL/GARDASIL 9 and lower sales of SIMPONI
and REMICADE, reflecting the transfer of marketing rights in former Merck territories back to
Johnson & Johnson.
Full-year 2024 Animal Health sales grew 4% to $5.9 billion. Excluding the unfavorable
impact of foreign exchange, Animal Health sales grew 8%. Approximately 2 percentage points
of the negative impact of foreign exchange were due to devaluation of the Argentine peso,
which were largely offset by inflation-related price increases, consistent with practice in that

-- 5 of 15 --

- 6 -
market. Full-year sales growth was primarily driven by higher pricing across both the
Companion Animal and Livestock product portfolios, and higher demand for poultry and swine
products, as well as sales related to the acquisition of the Elanco aqua business. Sales of
BRAVECTO were $1.1 billion in 2024, which represented growth of 6%, or 8% excluding the
impact of foreign exchange.
Fourth-Quarter and Full-Year Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Fourth Quarter 2024
Cost of sales $3,828 $701 $121 $- $3,006
Selling, general and administrative 2,864 29 16 - 2,819
Research and development 4,585 12 (1) - 4,574
Restructuring costs 51 - 51 - -
Other (income) expense, net 126 (31) - 152 5
Fourth Quarter 2023
Cost of sales $3,911 $454 $117 $- $3,340
Selling, general and administrative 2,804 24 29 - 2,751
Research and development 9,628 790 - - 8,838
Restructuring costs 255 - 255 - -
Other (income) expense, net 78 (35) - (61) 174
$ in millions GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Certain
Other
Items
Non-
GAAP2
Year Ended December 31, 2024
Cost of sales $15,193 $2,409 $495 $- $- $12,289
Selling, general and administrative 10,816 117 83 - - 10,616
Research and development 17,938 72 1 - - 17,865
Restructuring costs 309 - 309 - - -
Other (income) expense, net (24) (79) - 45 - 10
Year Ended December 31, 2023
Cost of sales $16,126 $2,018 $211 $- $- $13,897
Selling, general and administrative 10,504 86 122 - - 10,296
Research and development 30,531 819 1 - - 29,711
Restructuring costs 599 - 599 - - -
Other (income) expense, net 466 (47) - (279) 573 219
3 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 6 of 15 --

- 7 -
GAAP Expense, EPS and Related Information
Gross margin was 75.5% for the fourth quarter of 2024 compared with 73.3% for the
fourth quarter of 2023. The increase was primarily due to the favorable effects of product mix
(including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9) and foreign
exchange, partially offset by higher manufacturing-related costs (including inventory write-offs)
and higher amortization of intangible assets. Gross margin was 76.3% for the full year of 2024
compared with 73.2% for the full year of 2023. The increase was primarily due to the favorable
effects of product mix (including lower royalty rates related to KEYTRUDA and
GARDASIL/GARDASIL 9) and foreign exchange, partially offset by higher amortization of
intangible assets, as well as higher restructuring costs (primarily reflecting asset impairment
charges) and higher manufacturing-related costs (including inventory write-offs).
Selling, general and administrative (SG&A) expenses were $2.9 billion in the fourth
quarter of 2024, an increase of 2% compared with the fourth quarter of 2023. The increase was
primarily due to higher promotional and selling costs, partially offset by the favorable impact of
foreign exchange and lower restructuring costs. Full-year 2024 SG&A expenses were $10.8
billion, an increase of 3% compared with full-year 2023. The increase was primarily due to
higher administrative, promotional, selling and acquisition-related costs, partially offset by the
favorable impact of foreign exchange and lower restructuring costs.
Research and development (R&D) expenses were $4.6 billion in the fourth quarter of
2024, a decrease of 52% compared with the fourth quarter of 2023. R&D expenses were $17.9
billion for the full year of 2024, a decrease of 41% compared with the full year of 2023. The
declines in both the fourth quarter and full year of 2024 were primarily due to lower charges for
business development activity, lower intangible asset impairment charges, and the favorable
impact of foreign exchange, partially offset by increased compensation and benefit costs and
higher clinical development spending.
Other (income) expense, net, was $126 million of expense in the fourth quarter of 2024
compared with $78 million of expense in the fourth quarter of 2023. The unfavorability was
primarily due to net losses from investments in equity securities compared with net income from
investments in equity securities in the prior year quarter, partially offset by lower foreign
exchange losses and lower net interest expense. Other (income) expense, net, was $24 million
of income in the full year of 2024 compared with $466 million of expense in the full year of 2023,
primarily due to a $572.5 million charge in 2023 related to settlements with certain plaintiffs in
the Zetia antitrust litigation. The favorability was also due to $170 million of income related to
the expansion of an existing development and commercialization agreement with Daiichi
Sankyo, as well as lower foreign exchange losses in 2024. Other (income) expense, net, in the
full year of 2024 was unfavorably affected by lower net income from investments in equity
securities and higher net interest expense compared with 2023.
The effective tax rates of 10.2% and 14.1% for the fourth quarter and full year of 2024,
respectively, include a 6.2 percentage point favorable impact and a 2.6 percentage point
favorable impact, respectively, due to a reduction in reserves for unrecognized income tax

-- 7 of 15 --

- 8 -
benefits, resulting from the expiration of the statute of limitations for assessments related to
certain federal tax return years.
GAAP EPS was $1.48 for the fourth quarter of 2024 compared with a loss per share of
$0.48 for the fourth quarter of 2023, primarily driven by lower charges for business development
transactions, operational strength in the business, lower intangible asset impairment charges,
and a benefit from the expiration of the statute of limitations for assessments related to the 2020
federal tax return year. GAAP EPS was $6.74 for the full year of 2024 compared with EPS of
$0.14 for the full year of 2023. The increase was primarily driven by lower charges for business
development transactions, operational strength in the business, lower intangible asset
impairment charges, a benefit from the expiration of the statute of limitations for the 2020 and
2019 federal tax return years, and a charge in the prior year for settlements with certain plaintiffs
in the Zetia antitrust litigation, partially offset by the unfavorable effect of foreign exchange.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 80.8% for the fourth quarter of 2024 compared with 77.2%
for the fourth quarter of 2023. Non-GAAP gross margin was 80.8% for the full year of 2024
compared with 76.9% for the full year of 2023. The non-GAAP gross margin improvements in
both the fourth quarter and full year of 2024 were primarily due to the favorable effects of
product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9)
and foreign exchange, partially offset by higher manufacturing-related costs (including inventory
write-offs).
Non-GAAP SG&A expenses were $2.8 billion in the fourth quarter of 2024, an increase
of 2% compared with the fourth quarter of 2023. Non-GAAP SG&A expenses were $10.6 billion
for the full year of 2024, an increase of 3% compared with the full year of 2023. The increases
were primarily due to higher promotional and selling costs and, for the full year, higher
administrative costs, partially offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $4.6 billion in the fourth quarter of 2024, a decrease of
48% compared with the fourth quarter of 2023. Non-GAAP R&D expenses were $17.9 billion for
the full year of 2024, a decrease of 40% compared with the full year of 2023. The declines in
both the fourth quarter and full year of 2024 were primarily due to lower charges for business
development activity and the favorable impact of foreign exchange, partially offset by increased
compensation and benefit costs and higher clinical development spending.
Non-GAAP other (income) expense, net, was $5 million of expense in the fourth quarter
of 2024 compared with $174 million of expense in the fourth quarter of 2023. The favorability
was primarily due to lower foreign exchange losses and lower net interest expense. Non-GAAP
other (income) expense, net, was $10 million of expense in the full year of 2024 compared with
$219 million of expense in the full year of 2023. The favorability was primarily due to $170
million of income related to the expansion of an existing development and commercialization
agreement with Daiichi Sankyo, as well as lower foreign exchange losses in 2024, partially
offset by higher net interest expense.

-- 8 of 15 --

- 9 -
The non-GAAP effective tax rate was 16.2% for the fourth quarter and 16.8% for the full
year of 2024.
Non-GAAP EPS was $1.72 for the fourth quarter of 2024 compared with $0.03 for the
fourth quarter of 2023. Non-GAAP EPS was $7.65 for the full year of 2024 compared with EPS
of $1.51 for the full year of 2023. The increase in both periods was primarily driven by lower
charges for business development transactions and operational strength in the business. The
unfavorable effect of foreign exchange partially offset the increase in the full year.
A reconciliation of GAAP to non-GAAP net income (loss) and earnings (loss) per share
is provided in the table that follows.
Pipeline and Portfolio Highlights
Merck made important advancements in its broad, diverse pipeline, meeting significant
regulatory and clinical milestones throughout the fourth quarter.
In oncology, Merck announced positive topline results from the pivotal Phase 3 MK-
3475A-D77 trial evaluating the noninferiority of subcutaneous pembrolizumab and
berahyaluronidase alfa, in combination with chemotherapy, versus intravenous (IV) KEYTRUDA
administered with chemotherapy, for the first-line treatment of adult patients with metastatic
NSCLC. Subcutaneous pembrolizumab and berahyaluronidase alfa has the potential to improve
4 Includes the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments, as well as a $260 million benefit and a $519 million benefit in the fourth quarter and full year of 2024,
respectively, due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of
limitations for assessments related to certain federal tax return years. The benefit recognized in the fourth quarter of 2024 relates to
the 2020 federal tax return year and the benefit for the full year of 2024 relates to both the 2020 and 2019 federal tax return years.
Fourth Quarter Year Ended
$ in millions, except EPS amounts 2024 2023
Dec. 31,
2024
Dec. 31,
2023
EPS
GAAP EPS $1.48 $(0.48) $6.74 $0.14
Difference 0.24 0.51 0.91 1.37
Non-GAAP EPS that excludes items listed below2 $1.72 $0.03 $7.65 $1.51
Net Income (Loss)
GAAP net income (loss)1 $3,743 $(1,226) $17,117 $365
Difference 629 1,292 2,327 3,472
Non-GAAP net income that excludes items listed below1,2 $4,372 $66 $19,444 $3,837
Excluded Items:
Acquisition- and divestiture-related costs3 $711 $1,233 $2,519 $2,876
Restructuring costs 187 401 888 933
Loss (income) from investments in equity securities 152 (61) 45 (279)
Charge for Zetia antitrust litigation settlements - - - 573
Decrease to net income/increase to net loss before taxes 1,050 1,573 3,452 4,103
Estimated income tax (benefit) expense4 (421) (281) (1,125) (631)
Decrease to net income/increase to net loss $629 $1,292 $2,327 $3,472

-- 9 of 15 --

- 10 -
the patient experience and increase access for patients and health care providers compared to
IV administration.
Merck presented new data across multiple hematologic malignancies at the American
Society of Hematology Annual Meeting and Exposition in December 2024, including promising
Phase 2 data for its investigational antibody-drug conjugate zilovertamab vedotin for the
treatment of patients with previously untreated diffuse large B-cell lymphoma. With more than
20 abstracts presented, the data showcased Merck’s continued progress in advancing clinical
research for its expanding and diverse hematology pipeline.
Merck also achieved several key regulatory milestones in the U.S., Europe, Japan and
China. Highlights include the U.S. Food and Drug Administration (FDA) granting Breakthrough
Therapy designation to sacituzumab tirumotecan (sac-TMT) for the treatment of certain patients
with previously treated advanced or metastatic nonsquamous NSCLC with epidermal growth
factor receptor (EGFR) mutations. Additionally, Merck received new approvals for KEYTRUDA-
based regimens in Japan and China, as well as for WELIREG and Lynparza in China.
In vaccines and infectious diseases, the FDA accepted the Biologics License Application
(BLA) for clesrovimab, an investigational prophylactic long-acting monoclonal antibody designed
to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season
and set a Prescription Drug User Fee Act (PDUFA) date of June 10, 2025. This regulatory
milestone marks important progress toward having clesrovimab available in time for the 2025-26
RSV season. The filing was based on results from the pivotal Phase 2b/3 study of clesrovimab
in infants for the prevention of RSV that was presented at ID Week 2024. In addition, Merck
announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral,
two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with virologically
suppressed HIV-1 infection, in line with Merck’s commitment to help address the needs of
people living with HIV.
In January 2025, Merck also received expanded approval in China for GARDASIL. It is
now the first HPV vaccine approved in China for the prevention of certain HPV-related cancers
and diseases in males 9-26 years of age. In addition, the European Union’s (EU) Committee for
Medicinal Products for Human Use (CHMP) recommended the approval of CAPVAXIVE for
pneumococcal vaccination in adults, with a final decision for EU approval expected in the
second quarter of 2025.
In cardiovascular disease, Merck announced positive topline results from the Phase 3
ZENITH study, evaluating WINREVAIR in adults with pulmonary arterial hypertension (PAH)
with World Health Organization (WHO) Group 1 functional class (FC) III or IV at high risk of
mortality. Based on the positive results of an interim analysis, an independent data monitoring
committee recommended that the study be stopped early due to overwhelming efficacy. In
addition, in January 2025, Merck announced the Phase 3 HYPERION study evaluating
WINREVAIR in newly diagnosed adults with PAH with FC II or III at intermediate or high risk of
disease progression was also stopped early based on the positive results from the interim

-- 10 of 15 --

- 11 -
analysis of the ZENITH trial and a review of the totality of data from the WINREVAIR clinical
program to date. All participants in both the ZENITH and HYPERION studies will be offered the
opportunity to receive WINREVAIR as part of the open-label, long-term extension study,
SOTERIA.
Merck continued to execute on its business development strategy. The company
announced the closing of an exclusive global license for MK-2010, a novel investigational PD-
1/VEGF bispecific antibody from LaNova. Merck also entered into an exclusive global license
agreement with Hansoh to evaluate MK-4082, an investigational preclinical oral small molecule
glucagon-like peptide (GLP-1) receptor agonist.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Granted Breakthrough Therapy Designation to sac-TMT for
the Treatment of Certain Patients With Previously Treated
Advanced or Metastatic Nonsquamous NSCLC With EGFR
Mutations
(Read
Announcement)
FDA Granted Priority Review to Merck’s Application for
WELIREG for the Treatment of Patients With Advanced
Pheochromocytoma and Paraganglioma
(Read
Announcement)
Merck Received Positive EU CHMP Opinion for WELIREG as
Treatment for Adult Patients With Certain Types of Von Hippel-
Lindau (VHL) Disease-Associated Tumors and for Certain
Previously Treated Adult Patients With Advanced RCC, Based
on Results From Phase 2 LITESPARK-004 and Phase 3
LITESPARK-005 Trials
(Read
Announcement)
Merck Received Positive EU CHMP Opinion for KEYTRUDA
Plus Chemotherapy as First-Line Treatment for Adult Patients
With Unresectable Non-Epithelioid Malignant Pleural
Mesothelioma, Based on Results From Phase 2/3
IND.227/KEYNOTE-483 Trial
(Read
Announcement)
KEYTRUDA Approved in China in Combination With
Chemotherapy as Neoadjuvant Treatment, Then Continued as
Monotherapy After Surgery as Adjuvant Treatment for Patients
With Resectable Stage II, IIIA or IIIB NSCLC, Based on Results
From Phase 3 KEYNOTE-671 Trial
(Read
Announcement)
WELIREG Approved in China for Treatment of Adult Patients
With Certain Types of VHL Disease-Associated Tumors, Based
on Results From Phase 2 LITESPARK-004 Trial
(Read
Announcement)
Merck Announced Phase 3 MK-3475A-D77 Trial of
Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met
Primary Endpoints
(Read
Announcement)
Merck Announced Phase 3 KEYLYNK-001 Trial Met Primary
Endpoint of Progression-Free Survival in Patients With Advanced
Epithelial Ovarian Cancer
(Read
Announcement)
Lynparza Demonstrated Clinically Meaningful Prolonged Survival
Benefit in Early Breast Cancer, Based on Results From Phase 3
OlympiA Trial
(Read
Announcement)
Investigational Zilovertamab Vedotin in Combination With R-CHP
Demonstrated Complete Response Rate of 100% at 1.75
MG/KG Dose in Previously Untreated Patients With Diffuse
Large B-Cell Lymphoma, Based on Results From Phase 2
WaveLINE-007 Trial
(Read
Announcement)

-- 11 of 15 --

- 12 -
Vaccines
Merck Announced FDA Acceptance of BLA for Clesrovimab (MK-
1654), an Investigational Long-Acting Monoclonal Antibody
Designed to Protect Infants From RSV Disease During Their
First RSV Season; FDA Set PDUFA Date of June 10, 2025
(Read
Announcement)
Merck Received Expanded Approval of GARDASIL for Males in
China
(Read
Announcement)
Merck Received Positive EU CHMP Opinion for CAPVAXIVE for
Pneumococcal Vaccination in Adults
(Read
Announcement)
Merck Presented New Data From GARDASIL 9 Studies
Reinforcing Importance of Gender-Neutral HPV Vaccination in
Adults Up to Age 45 at International Papillomavirus Conference
2024
(Read
Announcement)
Cardiovascular
Merck Announced Pivotal Phase 3 ZENITH Trial Evaluating
WINREVAIR Met Primary Endpoint at Interim Analysis
(Read
Announcement)
Merck Announced Decision to Stop Phase 3 HYPERION Trial
Evaluating WINREVAIR Early and Move to Final Analysis
(Read
Announcement)
Infectious Diseases
Merck Announced Topline Results From Pivotal Phase 3 Trials
Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-
Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the
Treatment of Adults With Virologically Suppressed HIV-1
Infection
(Read
Announcement)
Full-Year 2025 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2025
Sales* $64.1 billion to $65.6 billion
Non-GAAP Gross margin2 Approximately 82.5%
Non-GAAP Operating expenses2** $25.4 billion to $26.4 billion
Non-GAAP Other (income) expense, net2 $300 million to $400 million expense
Non-GAAP Effective tax rate2 16.0% to 17.0%
Non-GAAP EPS2*** $8.88 to $9.03
Share count (assuming dilution) Approximately 2.53 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes $300 million for an anticipated milestone payment to LaNova associated with the technology transfer for MK-2010 expected to
be completed in 2025. Outlook does not assume any additional significant potential business development transactions.
***Includes expected one-time charge of approximately $0.09 per share related to the $300 million milestone payment to LaNova upon
completion of the technology transfer for MK-2010.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the company’s future GAAP results.
Merck anticipates full-year 2025 sales to be between $64.1 billion and $65.6 billion,
including a negative impact of foreign exchange of approximately 2% at mid-January 2025
exchange rates. This sales range reflects a decision to temporarily pause shipments of
GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year.

-- 12 of 15 --

- 13 -
Merck’s full-year non-GAAP effective income tax rate is expected to be between 16.0%
and 17.0%.
Merck expects full-year 2025 non-GAAP EPS to be between $8.88 and $9.03, including
a negative impact of foreign exchange of approximately $0.35 per share. This range includes an
expected one-time charge of $300 million, or approximately $0.09 per share, related to a
milestone payment to LaNova, which will be recognized upon completion of the technology
transfer for MK-2010. In 2024, non-GAAP EPS of $7.65 was negatively impacted by a net
charge of $1.28 per share related to certain asset acquisitions, licensing agreements and
collaborations.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Tuesday, Feb. 4, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties

-- 13 of 15 --

- 14 -
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site ( www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
Reblozyl (luspatercept)
REMICADE (infliximab)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
SIMPONI (golimumab)
VARIVAX (Varicella Virus Vaccine Live)

-- 14 of 15 --

- 15 -
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 15 of 15 --